Compounded Medication Margins in Telehealth: The Real Profit Numbers

Here's what nobody talks about in telehealth founder groups: the money. Everyone asks about compliance, provider licensing, and pharmacy partnerships. But the question that actually matters is simpler — how much can you keep?

I spent the last three months talking to 18 telehealth founders who run compounded medication businesses. I asked for real numbers. Not revenue — profit. What hits their bank account after pharmacy costs, provider fees, marketing, and the inevitable chargebacks.

The answers were uglier and more interesting than I expected.

The Margin Math Nobody Shows You

Let's start with the medication itself because that's where most telehealth founders get tripped up.

Brand-name medications — like Ozempic, Wegovy, and Mounjaro — carry list prices between $1,000-$1,350 per month. Most telehealth brands price these at $1,200-$1,500/month. The margin looks healthy on paper: 20-30%. But here's the problem — brand-name availability is a nightmare. Supply shortages mean you're constantly disappointing patients.

Compounded medications are where the business model gets interesting. Pharmacies can compound semaglutide, tirzepatide, and other active ingredients when the FDA declares a shortage — which it has for GLP-1s since 2022. The cost to the pharmacy varies, but most telehealth brands we're tracking pay between $200-$400 per month of medication (depending on dosage and pharmacy). Some report costs as low as $150/month for higher-volume orders.

Now here's where it gets murky. Some telehealth platforms mark up compounded medications 100-120% above cost. That means a $250/month medication gets sold to the patient for $500-$550. That 50% gross margin looks incredible — until you factor in everything else.

What You're Actually Keeping

I tracked five telehealth brands across three niches over 90 days. Here's the real breakdown:

Weight management (GLP-1s)

• Average patient revenue: $495/month
• Pharmacy cost (compounded): $220/month
• Gross margin: 55%
• Provider consultation fee: $75/month
• Marketing cost (CAC): $120/month
• Chargebacks/refunds: $35/month
• Net margin: ~$45/month per active patient

That's not a typo. After everything, a weight management brand is keeping roughly 9% of patient revenue. The brands doing best? They're keeping $60-80/month per patient — but only after hitting scale (200+ active patients).

Men's health (ED, testosterone)

• Average patient revenue: $89/month
• Pharmacy cost: $25-35/month
• Gross margin: 65%
• Provider fee: $25/month
• Marketing CAC: $45/month
• Net margin: ~$15-25/month per patient

Men's health has lower revenue per patient but also lower pharmacy costs. The math works, but you need volume. Most founders in this space need 300-500 patients just to cover overhead.

Women's health (hormone therapy, skincare)

• Average patient revenue: $125/month
• Pharmacy cost: $40-60/month
• Gross margin: 52%
• Provider fee: $35/month
• Marketing CAC: $55/month
• Net margin: ~$20-30/month per patient

The women's health space is interesting because retention is higher. Patients stay on HRT for years, not months. Lifetime value matters more than monthly margin.

The Pharmacy Cost Variable

Here's the part that surprised me most: pharmacy cost varies by 2-3x depending on who you use.

The telehealth brands making $80K+ monthly all had one thing in common — they've negotiated pharmacy rates. They use pharmacy benefit managers (PBMs) or work with compounding pharmacies directly at volume. A brand doing 500 patients/month might pay $180/month for the same medication a brand with 50 patients pays $320 for.

Some platforms charge a markup on pharmacy costs. Others pass through the actual cost and make money on the provider fee. Rimo Health, for example, charges zero markup on medications — the pharmacy cost passes through at cost. That changes the margin calculation entirely.

If you're evaluating a telehealth platform, ask this: What's the actual pharmacy cost, and do you add a markup? That single question can mean the difference between a viable business model and one that bleeds money.

Why Most Brands Lose Money (And How to Avoid It)

Three mistakes kill telehealth brands before month six:

1. Pricing too low. Some founders see $500/month for GLP-1s and think it's too expensive. They price at $350. Then they realize they can't cover provider costs, marketing eats the rest, and they're working for free. Pricing below $450/month for compounded GLP-1s almost always results in negative net margin.

2. Ignoring customer acquisition cost. The telehealth space has gotten expensive. CAC for GLP-1 keywords runs $80-150 on Meta. TikTok is cheaper ($30-60) but conversion is lower. Most new brands spend $100+ per patient acquired and never recover that investment before patients churn.

3. Not building retention. This is the biggest missed opportunity. A weight loss patient who stays for 12 months generates $540+ in net profit. One who churns at month 3 generates $135. The difference between a sustainable business and a money pit often comes down to patient experience — follow-ups, coaching, community.

What Successful Brands Do Differently

The telehealth brands doing $100K+ monthly have figured out a few things:

They bundle services. Instead of selling medication alone, they package it with coaching, labs, and follow-ups. This increases average revenue per patient by 30-50% and improves retention.

They treat marketing as a funnel, not a channel. Top brands run patient journeys that start with free content, move to low-cost consultations, and convert to medication programs. One founder told me her Instagram Reels drove 60% of her patient acquisitions — but the actual conversion happened through a $29 initial consult, not a cold sale.

They obsess over the first 90 days. Patient churn is highest in the first three months. Brands that have structured onboarding programs — check-ins at week 1, week 4, and week 12 — see 40% higher retention than those that don't.

The Bottom Line on Margins

Compounded medication telehealth can be profitable. But it's not the 70% margin business some people imagine. The real number, after all costs, is closer to 10-20% net margin — and that's for brands that have figured things out.

What makes the model work isn't the medication margin. It's lifetime value. It's retention. It's building a patient relationship that lasts years, not months.

If you're evaluating this space, the question isn't "Can I make money?" It's "Can I build a patient experience worth staying for?" That's where the profit actually lives.

What to Do Next

If you're serious about launching a compounded medication telehealth brand, here's your action path:

1. Get clear on your niche. Weight management has the highest revenue per patient but also the highest marketing costs. Men's health is more forgiving on CAC but requires volume. Women's health has the best retention. Pick based on your audience, not just margin.

2. Negotiate pharmacy costs. Don't accept the first pharmacy partnership offered. Get quotes from multiple compounding pharmacies. If a platform marks up pharmacy costs 100%+, that's a red flag.

3. Build retention into your model. Plan for the first 90 days before you launch. How will you onboard patients? What follow-ups will you offer? What's your churn prevention strategy?

4. Start with realistic unit economics. Use the numbers in this post as a sanity check. If a platform promises 60%+ net margins, ask what's being left out. The math doesn't lie.

The telehealth opportunity is real. But it's a business, not a get-rich-quick play. The founders who win are the ones who treat it that way.